Denali Therapeutics reinstated with a Market Perform at Raymond James

Raymond James reinstated coverage of Denali Therapeutics with a Market Perform rating and no price target Denali was able to secure an agreement from the FDA on an accelerated approval pathway for DNL310 in Hunters,and the firm’s model reflects approval and launch by late 2025, the analyst tells investors in a research note. At the same time, the firm says the stock is already pricing in the full opportunity and continues to view most of the pipeline as high-risk and early.